Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/12/2023 | 212.77% | Truist Securities | $20 → $18 | Maintains | Buy |
06/26/2023 | 386.53% | Oppenheimer | → $28 | Assumes | → Outperform |
06/20/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
06/16/2023 | 508.17% | Canaccord Genuity | → $35 | Reiterates | Buy → Buy |
06/05/2023 | 160.64% | JMP Securities | → $15 | Reiterates | → Market Outperform |
06/05/2023 | 160.64% | EF Hutton | → $15 | Reiterates | Buy → Buy |
05/26/2023 | 160.64% | EF Hutton | → $15 | Reiterates | Buy → Buy |
05/05/2023 | 160.64% | JMP Securities | $19 → $15 | Maintains | Outperform |
05/05/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
05/04/2023 | 30.32% | Stifel | $8 → $7.5 | Maintains | Hold |
05/04/2023 | 160.64% | RBC Capital | → $15 | Reiterates | → Outperform |
04/20/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
04/18/2023 | 230.15% | JMP Securities | → $19 | Reiterates | → Market Outperform |
04/17/2023 | 160.64% | EF Hutton | → $15 | Maintains | Buy |
04/04/2023 | 299.65% | HC Wainwright & Co. | $29 → $23 | Maintains | Buy |
03/21/2023 | 4.26% | Bernstein | → $6 | Initiates Coverage On | → Market Perform |
03/02/2023 | 438.66% | Goldman Sachs | $35 → $31 | Maintains | Buy |
03/02/2023 | 230.15% | JMP Securities | $23 → $19 | Maintains | Market Perform |
03/01/2023 | 282.28% | RBC Capital | $32 → $22 | Maintains | Outperform |
03/01/2023 | 386.53% | Oppenheimer | $32 → $28 | Maintains | Outperform |
03/01/2023 | 438.66% | Goldman Sachs | $35 → $31 | Maintains | Buy |
03/01/2023 | 160.64% | EF Hutton | → $15 | Reiterates | → Buy |
01/24/2023 | 91.14% | JP Morgan | $20 → $11 | Upgrades | Neutral → Overweight |
01/06/2023 | 108.51% | Baird | → $12 | Upgrades | Neutral → Outperform |
01/05/2023 | 160.64% | EF Hutton | → $15 | Initiates Coverage On | → Buy |
12/12/2022 | 56.39% | B of A Securities | → $9 | Downgrades | Buy → Underperform |
11/21/2022 | 403.91% | HC Wainwright & Co. | $43 → $29 | Maintains | Buy |
09/22/2022 | 212.77% | B. Riley Securities | $21 → $18 | Maintains | Buy |
08/10/2022 | 508.17% | Oppenheimer | $40 → $35 | Maintains | Outperform |
08/10/2022 | 456.04% | RBC Capital | $35 → $32 | Maintains | Outperform |
08/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
07/15/2022 | 456.04% | Goldman Sachs | $9 → $32 | Upgrades | Neutral → Buy |
06/03/2022 | 91.14% | Baird | → $11 | Initiates Coverage On | → Neutral |
05/24/2022 | 56.39% | Goldman Sachs | $12 → $9 | Maintains | Neutral |
05/05/2022 | 125.89% | Raymond James | $36 → $13 | Maintains | Outperform |
03/07/2022 | 108.51% | Goldman Sachs | $20 → $12 | Maintains | Neutral |
12/14/2021 | 508.17% | RBC Capital | $45 → $35 | Maintains | Outperform |
10/12/2021 | 369.16% | JMP Securities | $53 → $27 | Maintains | Market Outperform |
10/08/2021 | — | Stifel | Downgrades | Buy → Hold | |
10/08/2021 | 681.93% | RBC Capital | $55 → $45 | Maintains | Outperform |
10/08/2021 | 247.52% | Goldman Sachs | $71 → $20 | Downgrades | Buy → Neutral |
09/24/2021 | 525.54% | Raymond James | → $36 | Upgrades | Market Perform → Outperform |
09/23/2021 | 525.54% | Raymond James | → $36 | Upgrades | Market Perform → Outperform |
05/20/2021 | 612.42% | Truist Securities | $34 → $41 | Upgrades | Hold → Buy |
05/14/2021 | 803.56% | B. Riley Securities | → $52 | Initiates Coverage On | → Buy |
03/01/2021 | 647.18% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
01/26/2021 | 647.18% | Stifel | $33 → $43 | Upgrades | Hold → Buy |
12/10/2020 | 595.05% | HC Wainwright & Co. | → $40 | Assumes | → Buy |
10/23/2020 | 855.69% | RBC Capital | → $55 | Initiates Coverage On | → Outperform |
06/12/2020 | 751.43% | HC Wainwright & Co. | $55 → $49 | Maintains | Buy |
06/01/2020 | 855.69% | Oppenheimer | $50 → $55 | Maintains | Outperform |
06/01/2020 | — | Raymond James | Downgrades | Outperform → Market Perform | |
05/19/2020 | 942.57% | Roth Capital | → $60 | Upgrades | Neutral → Buy |
05/15/2020 | — | Guggenheim | Upgrades | Neutral → Buy | |
05/14/2020 | 664.55% | Canaccord Genuity | $36 → $44 | Maintains | Buy |
05/14/2020 | 768.81% | Oppenheimer | $44 → $50 | Maintains | Outperform |
05/14/2020 | 629.8% | HC Wainwright & Co. | $35 → $42 | Reiterates | → Buy |
05/14/2020 | 456.04% | SunTrust Robinson Humphrey | $29 → $32 | Downgrades | Buy → Hold |
04/13/2020 | 403.91% | SunTrust Robinson Humphrey | → $29 | Initiates Coverage On | → Buy |
02/24/2020 | 369.16% | Berenberg | → $27 | Initiates Coverage On | → Hold |
12/18/2019 | 542.92% | JMP Securities | → $37 | Initiates Coverage On | → Market Outperform |
11/04/2019 | 525.54% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
08/09/2019 | 542.92% | BTIG | → $37 | Initiates Coverage On | → Buy |
06/05/2019 | 351.78% | Roth Capital | → $26 | Initiates Coverage On | → Neutral |
05/31/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
05/23/2019 | 369.16% | Stifel | → $27 | Initiates Coverage On | → Hold |
05/03/2019 | 681.93% | Oppenheimer | → $45 | Initiates Coverage On | → Outperform |
03/29/2019 | 768.81% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
03/15/2019 | 595.05% | Raymond James | → $40 | Initiates Coverage On | → Outperform |
03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
11/05/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
11/05/2018 | 403.91% | JP Morgan | → $29 | Initiates Coverage On | → Neutral |
11/05/2018 | 438.66% | Jefferies | → $31 | Initiates Coverage On | → Buy |
11/05/2018 | 612.42% | Goldman Sachs | → $41 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
07/12/2023 | 212.77% | 信託證券 | 20 美元 → 18 美元 | 維護 | 購買 |
06/26/2023 | 386.53% | 奧本海默 | → 28 美元 | 假設 | → 跑贏大盤 |
06/20/2023 | 299.65% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
06/16/2023 | 508.17% | Canaccord Genu | → 35 美元 | 重申 | 購買 → 購買 |
06/05/2023 | 160.64% | JMP 證券 | → 15 美元 | 重申 | → 市場跑贏大盤 |
06/05/2023 | 160.64% | EF Hutton | → 15 美元 | 重申 | 購買 → 購買 |
05/26/2023 | 160.64% | EF Hutton | → 15 美元 | 重申 | 購買 → 購買 |
05/05/2023 | 160.64% | JMP 證券 | 19 美元 → 15 美元 | 維護 | 跑贏大盤 |
05/05/2023 | 299.65% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
05/04/2023 | 30.32% | Stifel | 8 美元 → 7.5 美元 | 維護 | 保持 |
05/04/2023 | 160.64% | 加拿大皇家銀行資本 | → 15 美元 | 重申 | → 跑贏大盤 |
04/20/2023 | 299.65% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
04/18/2023 | 230.15% | JMP 證券 | → 19 美元 | 重申 | → 市場跑贏大盤 |
04/17/2023 | 160.64% | EF Hutton | → 15 美元 | 維護 | 購買 |
04/04/2023 | 299.65% | HC Wainwright & Co. | 29 美元 → 23 美元 | 維護 | 購買 |
03/21/2023 | 4.26% | 伯恩斯坦 | → 6 美元 | 啓動覆蓋開啓 | → 市場表現 |
03/02/2023 | 438.66% | 高盛 | 35 美元 → 31 美元 | 維護 | 購買 |
03/02/2023 | 230.15% | JMP 證券 | 23 美元 → 19 美元 | 維護 | 市場表現 |
03/01/2023 | 282.28% | 加拿大皇家銀行資本 | 32 美元 → 22 美元 | 維護 | 跑贏大盤 |
03/01/2023 | 386.53% | 奧本海默 | 32 美元 → 28 美元 | 維護 | 跑贏大盤 |
03/01/2023 | 438.66% | 高盛 | 35 美元 → 31 美元 | 維護 | 購買 |
03/01/2023 | 160.64% | EF Hutton | → 15 美元 | 重申 | → 購買 |
01/24/2023 | 91.14% | 摩根大通 | 20 美元 → 11 美元 | 升級 | 中性 → 超重 |
01/06/2023 | 108.51% | 貝爾德 | → 12 美元 | 升級 | 中性 → 跑贏大盤 |
01/05/2023 | 160.64% | EF Hutton | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
2022 年 12 月 12 日 | 56.39% | B of A 證券 | → 9 美元 | 降級 | 買入 → 表現不佳 |
11/21/2022 | 403.91% | HC Wainwright & Co. | 43 美元 → 29 美元 | 維護 | 購買 |
2022 年 9 月 22 日 | 212.77% | B. 萊利證券 | 21 美元 → 18 美元 | 維護 | 購買 |
08/10/2022 | 508.17% | 奧本海默 | 40 美元 → 35 美元 | 維護 | 跑贏大盤 |
08/10/2022 | 456.04% | 加拿大皇家銀行資本 | 35 美元 → 32 美元 | 維護 | 跑贏大盤 |
08/10/2022 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
07/15/2022 | 456.04% | 高盛 | 9 美元 → 32 美元 | 升級 | 中性 → 買入 |
06/03/2022 | 91.14% | 貝爾德 | → 11 美元 | 啓動覆蓋開啓 | → 中立 |
2022 年 5 月 24 日 | 56.39% | 高盛 | 12 美元 → 9 美元 | 維護 | 中立 |
05/05/2022 | 125.89% | 雷蒙德·詹姆 | 36 美元 → 13 美元 | 維護 | 跑贏大盤 |
03/07/2022 | 108.51% | 高盛 | 20 美元 → 12 美元 | 維護 | 中立 |
12/14/2021 | 508.17% | 加拿大皇家銀行資本 | 45 美元 → 35 美元 | 維護 | 跑贏大盤 |
2021 年 12 月 10 日 | 369.16% | JMP 證券 | 53 美元 → 27 美元 | 維護 | 市場跑贏大盤 |
2021 年 8 月 10 日 | — | Stifel | 降級 | 買入 → 持有 | |
2021 年 8 月 10 日 | 681.93% | 加拿大皇家銀行資本 | 55 美元 → 45 美元 | 維護 | 跑贏大盤 |
2021 年 8 月 10 日 | 247.52% | 高盛 | 71 美元 → 20 美元 | 降級 | 買入 → 中性 |
2021 年 9 月 24 日 | 525.54% | 雷蒙德·詹姆 | → 36 美元 | 升級 | 市場表現 → 跑贏大盤 |
2021 年 9 月 23 日 | 525.54% | 雷蒙德·詹姆 | → 36 美元 | 升級 | 市場表現 → 跑贏大盤 |
2021 年 5 月 20 日 | 612.42% | 信託證券 | 34 美元 → 41 美元 | 升級 | 持有 → 買入 |
05/14/2021 | 803.56% | B. 萊利證券 | → 52 美元 | 啓動覆蓋開啓 | → 購買 |
2021 年 1 月 3 日 | 647.18% | HC Wainwright & Co. | 40 美元 → 43 美元 | 維護 | 購買 |
2021 年 1 月 26 日 | 647.18% | Stifel | 33 美元 → 43 美元 | 升級 | 持有 → 買入 |
2020 年 10 月 12 日 | 595.05% | HC Wainwright & Co. | → 40 美元 | 假設 | → 購買 |
2020 年 10 月 23 日 | 855.69% | 加拿大皇家銀行資本 | → 55 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
2020 年 12 月 6 日 | 751.43% | HC Wainwright & Co. | 55 美元 → 49 美元 | 維護 | 購買 |
2020 年 1 月 6 日 | 855.69% | 奧本海默 | 50 美元 → 55 美元 | 維護 | 跑贏大盤 |
2020 年 1 月 6 日 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
2020 年 5 月 19 日 | 942.57% | 羅斯資本 | → 60 美元 | 升級 | 中性 → 買入 |
05/15/2020 | — | 古根海姆 | 升級 | 中性 → 買入 | |
05/14/2020 | 664.55% | Canaccord Genu | 36 美元 → 44 美元 | 維護 | 購買 |
05/14/2020 | 768.81% | 奧本海默 | 44 美元 → 50 美元 | 維護 | 跑贏大盤 |
05/14/2020 | 629.8% | HC Wainwright & Co. | 35 美元 → 42 美元 | 重申 | → 購買 |
05/14/2020 | 456.04% | SunTrust 羅賓遜漢弗萊 | 29 美元 → 32 美元 | 降級 | 買入 → 持有 |
2020 年 4 月 13 日 | 403.91% | SunTrust 羅賓遜漢弗萊 | → 29 美元 | 啓動覆蓋開啓 | → 購買 |
2020 年 2 月 24 日 | 369.16% | 貝倫貝格 | → 27 美元 | 啓動覆蓋開啓 | → 按住 |
2019 年 12 月 18 日 | 542.92% | JMP 證券 | → 37 美元 | 啓動覆蓋開啓 | → 市場跑贏大盤 |
11/04/2019 | 525.54% | Canaccord Genu | → 36 美元 | 啓動覆蓋開啓 | → 購買 |
08/09/2019 | 542.92% | BTIG | → 37 美元 | 啓動覆蓋開啓 | → 購買 |
06/05/2019 | 351.78% | 羅斯資本 | → 26 美元 | 啓動覆蓋開啓 | → 中立 |
05/31/2019 | — | 古根海姆 | 啓動覆蓋開啓 | → 中立 | |
05/23/2019 | 369.16% | Stifel | → 27 美元 | 啓動覆蓋開啓 | → 按住 |
05/03/2019 | 681.93% | 奧本海默 | → 45 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
03/29/2019 | 768.81% | 派珀·桑德勒 | → 50 美元 | 啓動覆蓋開啓 | → 超重 |
03/15/2019 | 595.05% | 雷蒙德·詹姆 | → 40 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
2019 年 3 月 14 日 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
11/05/2018 | — | Cowen & Co. | 啓動覆蓋開啓 | → 跑贏大盤 | |
11/05/2018 | 403.91% | 摩根大通 | → 29 美元 | 啓動覆蓋開啓 | → 中立 |
11/05/2018 | 438.66% | 傑富瑞 | → 31 美元 | 啓動覆蓋開啓 | → 購買 |
11/05/2018 | 612.42% | 高盛 | → 41 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Allogene Therapeutics (ALLO)?
Allogene Therapeutics(ALLO)的目標價格是多少?
The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by Truist Securities on July 12, 2023. The analyst firm set a price target for $18.00 expecting ALLO to rise to within 12 months (a possible 212.77% upside). 32 analyst firms have reported ratings in the last year.
Truist Securities於2023年7月12日公佈了Allogene Therapeutics(納斯達克股票代碼:ALLO)的最新目標股價。這家分析公司將目標股價定爲18.00美元,預計ALLO將在12個月內升至12.77%(可能上漲212.77%)。去年有32家分析公司公佈了評級。
What is the most recent analyst rating for Allogene Therapeutics (ALLO)?
分析師對Allogene Therapeutics(ALLO)的最新評級是多少?
The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by Truist Securities, and Allogene Therapeutics maintained their buy rating.
Allogene Therapeutics(納斯達克股票代碼:ALLO)的最新分析師評級由Truist Securities提供,Allogene Therapeutics維持買入評級
When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?
Allogene Therapeutics(ALLO)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Allogene Therapeutics的高管和客戶交談,以及聽取財報電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。Allogene Therapeutics的最後一次評級是在2023年7月12日提交的,因此你應該預計下一個評級將在2024年7月12日左右公佈。
Is the Analyst Rating Allogene Therapeutics (ALLO) correct?
分析師對Allogene Therapeutics (ALLO) 的評級正確嗎
While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a maintained with a price target of $20.00 to $18.00. The current price Allogene Therapeutics (ALLO) is trading at is $5.76, which is out of the analyst's predicted range.
儘管評級是主觀的,將會發生變化,但最新的Allogene Therapeutics(ALLO)評級維持不變,目標股價爲20.00美元至18.00美元。Allogene Therapeutics(ALLO)目前的交易價格爲5.76美元,超出了分析師的預測區間。